Business
GENFIT Announces Advances Across its ACLF Pipeline at AASLD The Liver Meeting® 2025
Several posters and presentations featuring new data on three ACLF programs, including G1090N (NTZ reformulation) disease model data, new real-world data and biomarker insights in cirrhosisNew Iqirvo® PBC and PSC data to be presented by partner Ipsen, underscoring its potential in rare cholestatic liver diseases Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), October 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving
About this update from Genfit Sa
[{"type":"list","items":[{"val":[{"type":"text","content":"Several posters and presentations featuring new data on three ACLF programs, including G1090N (NTZ reformulation) disease model data, new real-world data and biomarker insights in cirrhosis","length":189,"tagName":"p"}]},{"val":[{"type":"text","content":"New Iqirvo® PBC and PSC data to be presented by partner Ipsen, underscoring its potential in rare cholestatic liver diseases","length":124,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":313,"olType":false},{"type":"text","content":"Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), October 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its participation at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025 in Washington, D.C., November 7-11, 2025.","length":431,"tagName":"p"},{"type":"text","content":"GENFIT will present new data highlighting the potential of its pipeline in Acute on-Chronic Liver Failure (ACLF):","length":113,"tagName":"p"},{"type":"text","content":"G1090N (reformulation of nitazoxanide) – Poster #4165: Efficacy of nitazoxanide (NTZ) on systemic inflammation and organ function in disease models of Acute-on-Chronic Liver Failure (ACLF) when administered post-ACLF trigger","length":224,"tagName":"p"},{"type":"text","content":"Authors: Bobowski-Gerard, M. et al","length":34,"tagName":"p"},{"type":"text","content":"Session: Acute-on-Chronic Liver Failure","length":39,"tagName":"p"},{"type":"text","content":"Date & Time: November 10, 2025 (8.00 am – 5.00 pm)","length":54,"tagName":"p"},{"type":"text","content":"G1090N is the lead program in GENFIT’s ACLF pipeline. Clinical safety data and markers of early efficacy are expected at the end of the year.","length":141,"tagName":"p"},{"type":"text","content":"SRT-015 – Poster #4171: ASK1 inhibitor SRT-015 reduces systemic inflammation while promoting immune host defense mechanisms in preclinical in vitro and in vivo models related to ACLFAuthors: Legry, V. et al","length":207,"tagName":"p"},{"type":"text","content":"Session: Acute-on-Chronic Liver Failure","length":39,"tagName":"p"},{"type":"text","content":"Date & Time: November 10, 2025 (8.00 am – 5.00 pm)"...